New Mexico Tech and NCGR Join to Create the New Mexico Genome Sequencing Center
News Jan 15, 2007
The New Mexico Institute of Mining and Technology (NMT), Socorro, NM, and the National Center for Genome Resources (NCGR), Santa Fe, NM, have announced that they have established a partnership to create the New Mexico Genome Sequencing Center (NMGSC).
The State of New Mexico has provided $600,000 in funding to establish the Center, which will be located at NCGR in Santa Fe. The NMGSC will be the first in the nation to focus on medical resequencing.
Medical resequencing is an approach for discovery of the genetic basis of common human diseases or important crop traits. It refers to the large scale sequencing of the genome of many individuals affected by a disease or with a trait of interest.
“The New Mexico Genome Sequencing Center is being established to serve the needs of researchers at all New Mexico universities and research institutes,” stated Dr. Daniel H. López, President of NMT. “The NMGSC will focus on problems that are important to New Mexicans.”
Initial NMGSC programs will include sequencing the genome of the major pathogen of chile crops and the Schizophrenia Genome Project.
Chile pathogen sequencing is being undertaken in collaboration with the Joint Genome Institute of the Department of Energy, Walnut Creek, CA, and 454 LifeSciences Inc., New Haven, CT, and is funded by grants from the US Department of Agriculture, National Science Foundation and the Department of Energy.
The Schizophrenia Genome Project is being undertaken in collaboration with the MIND Institute and University of New Mexico, Albuquerque, NM.
Stated Dr. Stephen F. Kingsmore, President of NCGR, “Medical resequencing is a natural extension of fourteen years of experience by NCGR in software development for DNA sequence analysis. We believe that the NMGSC will attract biotechnology and pharmaceutical interest to the region.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.